Daysi Caceres
Family · Dunnellon, FLNPI 1285024430
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 774 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $3,867 and has fallen 77.2% since, to $883 in 2025. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 774 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- AbbVie$2K
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$1K
- plus $5K from 33 others
What the payments were for
- Food & beverage$14,75299%
- Education$1161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 87 | $2,479 |
| GSK | 116 | $1,713 |
| AbbVie | 73 | $1,632 |
| Novo Nordisk | 84 | $1,602 |
| Lilly USA, LLC | 88 | $1,362 |
| Boehringer Ingelheim | 54 | $1,077 |
| Pfizer | 38 | $745 |
| Johnson & Johnson | 37 | $599 |
| Sanofi-aventis U.S. LLC | 25 | $427 |
| Bayer | 20 | $365 |
| Amgen | 21 | $364 |
| Astellas Pharma US Inc | 16 | $345 |
| Amarin Pharma, Inc. | 11 | $247 |
| Merck | 14 | $233 |
| Lexicon Pharmaceuticals, Inc. | 11 | $210 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $184 |
| Kowa Pharmaceuticals America, Inc. | 11 | $179 |
| Esperion Therapeutics, Inc. | 8 | $178 |
| Novartis | 8 | $133 |
| Idorsia Pharmaceuticals US Inc | 5 | $90 |
| Biogen | 6 | $86 |
| Harmony Biosciences LLC | 3 | $73 |
| Jazz Pharmaceuticals Inc. | 5 | $72 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $69 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Eisai Inc. | 3 | $40 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Alkermes, Inc. | 1 | $28 |
| Corium, LLC | 1 | $27 |
| Abbott | 1 | $25 |
| Smith+Nephew | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Boston Scientific | 1 | $19 |
| Valinor Pharma, LLC | 1 | $19 |
| Orexo US, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| UCB, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,868 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Famotidine | 20 | $225 |
Paid to pharmacies, not to this prescriber.
Other family in Dunnellon
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.